TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03963180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coffee
Description: All patients were asked to drink the entire 150-mL amounts within 20 minutes under the supervision of a nurse or doctor. Patients were free to drink any amount of water but no more coffee, black tea, or other forms of caffeine, such as soda. Coffee and hot water were prepared with a conventional coffee machine (Nescafe Alegria; 100 g caffeine; Nestlé. Gatwick, United Kingdom).
Study: NCT02742714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam SBC system
Description: The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
Study: NCT01349933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor MK2206
Description: Given PO
Study: NCT03514979

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Polysaccharide Conjugate vaccination and Pneumococcal Polysaccharide Vaccination
Description: Pneumococcal vaccines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Polysaccharide Conjugate vaccination and Pneumococcal Polysaccharide Vaccination
Description: Pneumococcal vaccines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Polysaccharide Conjugate vaccination and Pneumococcal Polysaccharide Vaccination
Description: Pneumococcal vaccines
Study: NCT03090451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic physical exercise on treadmill, with intensity based on prior VO2-max testing during the screening visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic physical exercise on treadmill, with intensity based on prior VO2-max testing during the screening visit.
Study: NCT02380859

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prism adaptation
Description: Prism adaptation is one type of sensorimotor adaptation. Prism adaptation described any adaptation to a prismatic shift in vision (i.e. any magnitude or direction of shift). In this study we are using adaptation to upward-shifting prisms, which induces a downward sensorimotor after-effect.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Prism adaptation
Description: Prism adaptation is one type of sensorimotor adaptation. Prism adaptation described any adaptation to a prismatic shift in vision (i.e. any magnitude or direction of shift). In this study we are using adaptation to upward-shifting prisms, which induces a downward sensorimotor after-effect.
Study: NCT03887117

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IQOS + Exercise Training Program
Description: Switch to IQOS use + participation in a training program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IQOS without Exercise Training Program
Description: Switch to IQOS use only, without participation in a training program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette Smoking + Exercise Training Program
Description: Continue to smoke cigarettes + participation in a training program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Abstinence + Exercise Training Program
Description: Switch to smoking abstinence + participation in a training program
Study: NCT02135705

Intervention type: DRUG
Intervention: Lomitapide
Description: As prescribed by Physician.
Study: NCT03637530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inverse ratio ventilation
Description: during general anaesthesia in laparoscopic surgeries, this group of patients will receive inverse ratio ventilation with proper observation of hemodynamics
Study: NCT02809508

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oily fish
Description: A selection of oily fish, including salmon, herring and mackerel, provided for dinner and lunch

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Poultry
Description: A selection of poultry, mainly chicken, provided for dinner and lunch
Study: NCT03045393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine (IMGN853)
Description: Mirvetuximab Soravtansine is a targeted drug for tumors that express high levels of folate receptor alpha.
Study: NCT01373710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: One injection per week during 8 weeks by lumbar puncture or Ommaya Reservoir. 4 levels of doses are expected from 30 mg to 150 mg
Study: NCT02790593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juxta-Cures™
Description: Juxta-CURES™ is an adjustable compression device, which may be used as a secondary dressing for the treatment of open venous stasis ulcers. It is an inelastic wrap around device with a Built-In-Pressure System™, which allows patients to easily and accurately apply pressure to their own leg and adjust it throughout the day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Compression
Description: Compression bandaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoPress®
Description: Pressure monitoring to be done at time of bandage application and removal for both arms of the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PicoPress®
Description: Pressure monitoring to be done at time of bandage application and removal for both arms of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silhoutte® 3D wound imaging system
Description: Photographic imaging system to measure wound surface area and depth. Picture to be taken at each appointment. This intervention is for both arms of the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silhoutte® 3D wound imaging system
Description: Photographic imaging system to measure wound surface area and depth. Picture to be taken at each appointment. This intervention is for both arms of the study.
Study: NCT01899118

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation
Description: 50.4Gy/28F/5.5w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 400mg/w，0-5w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2 d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825mg/m2 bid d1-5/w,1-5w
Study: NCT02391870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT-PD
Description: Using an iterative process, the investigators modified MBCT to include a focus on perinatal depression (MBCT-PD). The modifications took into account developmental processes associated with the perinatal period, characteristics and correlates of perinatal depression, and the physical aspects of pregnancy.
Study: NCT01036633

Intervention type: DEVICE
Intervention: Infrared Thermometer
Description: The infrared thermometer will be used to grade the severity of oral mucositis in patients undergoing antineoplastic chemotherapy for multiple myeloma. The photothermal camera will be used to take intraoral digital images of the mouth.

Intervention type: DEVICE
Intervention: Infrared Thermometer
Description: The infrared thermometer will be used to grade the severity of oral mucositis in patients undergoing antineoplastic chemotherapy for multiple myeloma. The photothermal camera will be used to take intraoral digital images of the mouth.
Study: NCT00855322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gym exercise group intervention
Description: Gym based circuit class
Study: NCT03107975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human amniotic epithelial cells
Description: intrathecal injection of human amniotic epithelial cells
Study: NCT02273908

Intervention type: OTHER
Intervention: No intervention
Description: The study is observational

Intervention type: OTHER
Intervention: No intervention
Description: The study is observational
Study: NCT02325921

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: One MRI examination, diagnostic scanning protocol as used for renal tumours with additional diffusion weighted sequences, but without contrast enhancement.
Study: NCT04423575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient health care pathway
Description: A surgical procedure performed as an outpatient procedure means that the patient leaves the hospital before 8pm the same day. The surgery is identical but the standard care pathway is reinforced to insure a safe return to home.
Study: NCT04085159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen-specific T cells CART/CTL and DCvac
Description: Antigen-specific T cells CART/CTL and DCvac cells to treat cancer
Study: NCT00956605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer attention training systems for children with ADHD
Description: Computer attention training systems for children with ADHD, one with and one without EEG-biofeedback, were delivered via approximately 20 sessions to the participants

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer attention training systems for children with ADHD
Description: Computer attention training systems for children with ADHD, one with and one without EEG-biofeedback, were delivered via approximately 20 sessions to the participants
Study: NCT03721211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]Martinostat
Description: a type of dye used for radiographic imaging of the HDAC protein

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-PET scanner
Description: PET, or positron emission tomography, is a type of imaging test that uses a tracer, or dye, to make detailed pictures showing the activities of the cells that make up tissues and organs
Study: NCT03346304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy (PDT)
Description: Photodynamic Therapy (PDT) using photosensitiser drug Fotolon
Study: NCT05090306

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine ultrasound examination
Description: ULTRASOUND EXAMINATION Women recruited to take part in the study will undergo the routine ultrasound examinations and monitoring, including a fetal echocardiogram between 12-13+6 weeks of gestation (for the first trimester cases) and between 18-24 weeks of gestation (for the second trimester cases). Two-dimensional evaluation of each fetal heart will include a cine loop sweep obtained from the from the four-chamber view plane by moving the transducer cranially towards the upper mediastinum, allowing the visualization of the following planes: four-chamber view, left and right ventricular outflow tracts, three vessels and trachea view. The examination will be stored for further analysis.
Study: NCT03731026

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LightPath® Imaging System and 68Ga-RM2
Description: Imaging System:The LightPath® Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post-marketing study).~Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LightPath® Imaging System and 68Ga-RM2
Description: Imaging System:The LightPath® Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post-marketing study).~Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.

Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-RM2
Description: Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
Study: NCT03316066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stellate ganglion block with ropivacaine 0.2% 5 mL
Description: Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stellate ganglion block wit ropivacaine 0.2% 2 mL
Description: Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
Study: NCT01691703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolaryngoscope and Bonfils
Description: First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
Study: NCT03130140

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macroscopic on-site evaluation
Description: Macroscopic on-site evaluation: any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). Length of MVC will be measured to determine the adequacy of that puncture.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Conventional EUS-FNA
Study: NCT02612688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP Video Program
Description: The ACP Video Program consists of five videos that address ACP decisions: (1) General Goals of Care, (2) Goals of Care for Advanced Dementia, (3) Hospice, (4) Hospitalization, and (5) ACP for Healthy Patients. NH staff will offer videos to patients at these clinical triggers: (1) Within 7 days of admission or readmission; (2) Every 6 months for long-stay patients; (3) When there is a significant change in clinical status; (4) When a treatment decision arises for which there is a specific video; and (5) Special circumstances when goals of care are being considered (e.g., family visiting).
Study: NCT00855322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy group exercise intervention
Description: Hydrotherapy group exercise class

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control group
Description: No intervention
Study: NCT01475032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535
Description: CHF 1535 (BDP/FF) for 12 weeks
Study: NCT00567983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis
Description: Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Endura
Description: Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
Study: NCT02353871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: A solution containing 50 U in 0.25 mL (200 U/mL). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL, containing 50 U of BTX-A-HAC NG (i.e. 10 U/0.05 mL) was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A solution containing only the excipients of BTX-A-HAC NG (identical in appearance to the active product). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
Study: NCT02108847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: .2% Ropivacaine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia Iliaca Block
Description: Ultrasound-guided regional anesthesia block to the groin area.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Fascia Iliaca Block
Description: Ultrasound-guided regional anesthesia block to the groin area.
Study: NCT00571896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senna+ docusate
Description: Senna+Docusate: dose will be 8.6 mg senna concentrate with 50 mg docusate. The participants will take the medication as follows: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 \& 3 (2 tabs at night and in the morning) until the first-postoperative visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pill: The participants will use the placebo pills in the following manner: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 \& 3 (2 tabs at night and in the morning) until the first-postoperative visit.
Study: NCT04429035

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2
Description: Administration of 300 μg Vitamin K2 (MQ7) daily p.o

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 300 μg Vitamin K2 (MQ7) Placebo daily p.o
Study: NCT01584518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Based on clinical standard per clinician

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Based on clinical standard per clinician
Study: NCT04250688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso Training with FES
Study: NCT03739255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cacicol20
Description: Cacicol20 is supplied as a sterile single-dose solution of alpha 1-6 poly-carboxymethyl glucose sulfate One drop is instilled at each application to impregnate cornea.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ocluac is artificial tear which contains Hydroxypropylmethyl Cellulose and Sodium Chloride, It is presented in a 0.4 mL vial. One drop is delivered at each application.
Study: NCT01263925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil (Prostaglandin E1)
Description: 4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: 4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Pentoxifylline oral
Description: 4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Alprostadil (Prostaglandin E1) intravenous
Description: 4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.
Study: NCT02072421

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PCI
Study: NCT04580498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701+Paclitaxel+carboplatin
Description: Drug: SHR-1701 30mg/kg Drug: Paclitaxel 175mg/m2 Drug: Carboplatin AUC 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Drug: SHR-1701 30mg/kg
Study: NCT01888627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated care
Description: The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
Study: NCT01965106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QPI-1007 Injection
Description: 1.5 mg QPI-1007 Injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: (including placebo)
Description: Sham injection procedure
Study: NCT03272711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive training program
Description: Online training program, 30 minutes a day, 5 times a week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training program
Description: Online training program, 30 minutes a day, 5 times a week
Study: NCT00903071

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Real PPL
Description: See above arm description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sim PPL
Description: See above arm description